Drugs / SYX-5219
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07558668 | Feb 2025 → Aug 2026 overdue | atopic eczema | Sitryx Therapeutics Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-05-13 | Sitryx Therapeutics Ltd | Results First-in-Class Oral PKM2 Modulator SYX-5219 Phase 1a Trial Data to be Presented at SID 2026 sitryx.com ↗
SYX-5219 was safe and well tolerated across all doses, with no serious, unexpected or severe adverse events or treatment-related lab abnormalities. |
| 2026-01-26 | Sitryx Therapeutics Ltd | Results Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of immunomodulatory activity sitryx.com ↗
A recently completed Phase 1a clinical trial conducted in healthy volunteers in the UK demonstrated SYX-5219 was safe and well tolerated with predictable pharmacokinetics and robust target engagement. |
| 2025-11-12 | Sitryx Therapeutics Ltd | Results Sitryx presents new preclinical data highlighting PKM2 as a promising metabolic target for the treatment of atopic dermatitis at the Inflammatory Disease Skin Summit 2025 sitryx.com ↗
Preclinical data highlight that PKM2 modulation inhibits several important mechanisms underlying atopic dermatitis pathology |
| 2025-10-02 | Sitryx Therapeutics Ltd | Regulatory Sitryx receives FDA clearance of IND application for SYX-5219 for the treatment of atopic dermatitis sitryx.com ↗ |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYX-5219 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07558668 ↗ |
| Route | Oral | “Oral Capsule to be administered at each specific dose level within each cohort” NCT07558668 ↗ |